Please login to the form below

Not currently logged in
Email:
Password:

Revestive

This page shows the latest Revestive news and features for those working in and with pharma, biotech and healthcare.

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Orphan drugs dominate UK Prix Galien shortlist, medtech debuts

Seven companies have been shortlisted for the Orphan Product Award; Amicus (Galafold), Biogen (Spinraza), Biomarin (Brineura), Eusa (Qarziba), Intercept (Ocaliva), Kyowa Kirin (Crysvita) and Shire (Revestive).

Latest news

  • Relief for Shire as FDA clears NPS' Natpara Relief for Shire as FDA clears NPS' Natpara

    placebo. Natpara is NPS' second approved product after Gattex/Revestive (teduglutide), a GLP-2 analogue used for the long-term treatment of short bowel syndrome in adults that is expected to

  • Shire signs deal to buy NPS for $5.2bn Shire signs deal to buy NPS for $5.2bn

    Shire chief executive Flemming Ornskov said that the combined company would be able to drive sales of NPS' rare gastrointestinal (GI) disease therapy Gattex/Revestive (teduglutide), a GLP-2 analogue approved

  • European drug applications 'stable but more complex in 2012' European drug applications 'stable but more complex in 2012'

    is the first therapy to address the underlying mechanism of CF, and Takeda's Revestive (teduglutide) for treating adults with a rare but debilitating condition known as short bowel syndrome.

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • A rare talent A rare talent

    This is, he adds, “extremely restrictive”, and he points to Revestive (teduglutide), Shire's treatment for the rare and potentially fatal gastrointestinal disorder short bowel syndrome.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    Meanwhile, the company recently won approval for a brace of new products in Europe after regulators gave the greenlight to its short bowel syndrome drug Revestive (teduglutide) in September and approved

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Iguazu

Iguazu Ltd is a digital healthcare agency, delivering tactical and innovative solutions. WHAT WE DO We are Closed Loop Marketing...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....